Trimer-Tag antibodies

Endo180 has been shown to be a collagen receptor and functions in both collagen turnover and cell adhesion. The C-terminal region of collagen (C-prodomain, also known as CICP) was found to be involved in binding to Endo180. The C-prodomain of human Type I alpha collagen (Trimer-Tag) which is capable of self-trimerization via interchain disulfide bonds has been invented by Dr. Peng Liang, the founder of GenHunter, for producing recombinant trimeric biologics and viral antigens in vaccine development. S-Trimer is a SARS-CoV-2 COVID-19 vaccine candidate produced by Clover Biopharmaceuticals under an exclusive licensing agreement with GenHunter and has received close to $400 million dollars in support from CEPI in clinical development and commercialization. The resulting COVID vaccine (SCB-2019) received EUA approval in China in December 2022.

GenHunter has 1 mouse monoclonal antibody against human Trimer-Tag which is CICP from human Col I(alpha). In addition, we offer has 4 monoclonal antibodies against human Endo180 (a neutralizing mAb and 3 binding mAbs) plus a recombinant human Endo180-Fc fusion protein.